Must-read news from the week of May 16
A look at what the Contemporary Pediatrics® team covered this week.
This week’s top articles:
Donna Hallas discusses the Pfizer-BioNTech vaccine booster for children 5 to 11 years old
Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.
Butyrylcholiesterase may be key biomarker in SIDS identification, prevention
Investigators may have found a piece of the puzzle into what causes sudden infant death syndrome.
FDA implements increased flexibilities for foreign importation of infant formula
This week, the agency announced it is encouraging importation of infant formula from usually unutilized foreign means in hopes of increasing access to the product in the wake of the country-wide shortage.
House of Representatives democrats propose $28 million aid bill for infant formula shortage
The proposed aid bill would give the FDA funds to increase staff and prepare for future infant formula shortages.
More articles from this week:
Getting to the heart of pediatric vision loss and blindness
Seconds Matter: A Pearl for Improving Communication During Surgery
Study examines best practices for managing perinatal depression
Significant OSA prevalence in pediatric patients with pulmonary hypertension
First patient treated in adolescent epilepsy trial assessing NeuroPace RNS system
FDA Authorizes Pfizer-BioNTech Booster Shot for Children Ages 5 to 11
Self-tests for COVID-19 are accurate and tolerable for children
Sunscreen protection for children
Pfizer-BioNTech vaccine prevented more than 100,000 US deaths in 2021
Preexisting CV conditions may increase COVID-19 severity among pediatric patients
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
AAP advocates for increased action from White House, Congress on infant formula shortage
